UP!
| Industry | Pharmaceuticals |
|---|---|
| Founded | 2000 in Cambridge, Massachusetts |
| Headquarters | Cambridge, Massachusetts, United States |
|
Number of employees
|
426 (2016) |
| Website | www |
Merrimack Pharmaceuticals is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.
Merrimack first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in Europe the following year.
Merrimack was founded by a group of scientists from MIT and Harvard University in 2000.
In 2016, Merrimack had 426 full-time employees, 103 of which had an MD or PhD.
In October 2016, CEO Robert Mulroy resigned and the company announced they would be laying off 20% of its employees. In January 2017, interim CEO Gary Crocker resigned and the board of directors appointed Richard Peters to be president and CEO. Peters previously worked at Sanofi and was a faculty member at Harvard University.
In January 2017, French pharmaceutical company Ipsen announced they would be purchasing Onivyde from Merrimack for approximately $1 billion.
Merrimack has four drugs in clinical development.
| 2016-05-26 | Initiated Coverage | Robert W. Baird | Neutral | $8.00 |
| 2016-05-20 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2016-05-20 | Reiterated Rating | Mizuho | Buy | $13.00 |
| 2016-05-03 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-03 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-02-27 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2016-01-27 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2016-01-20 | Reiterated Rating | Mizuho | Positive to Buy | $13.00 |
| 2015-12-30 | Reiterated Rating | Oppenheimer | Buy | |
| 2015-12-30 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | |
| 2015-12-29 | Reiterated Rating | Mizuho | Buy | $16.00 to $13.00 |
| 2015-12-24 | Reiterated Rating | Oppenheimer | Buy | $15.00 |
| 2015-12-23 | Lower Price Target | Mizuho | Buy | $16.00 to $13.00 |
| 2015-10-27 | Boost Price Target | Oppenheimer | Outperform | $13.00 to $15.00 |
| 2015-10-23 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2015-10-22 | Reiterated Rating | Mizuho | Buy | $16.00 |
| 2015-10-06 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2015-09-22 | Reiterated Rating | Oppenheimer | Outperform | $13.00 |
| 2015-08-12 | Reiterated Rating | Mizuho | Outperform | $16.00 |
| 2015-08-12 | Initiated Coverage | Oppenheimer | Outperform | $13.00 |
| 2015-08-11 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2015-08-11 | Reiterated Rating | Cantor Fitzgerald | Buy | $16.00 |
| 2015-06-15 | Reiterated Rating | Cantor Fitzgerald | Buy | $16.00 |
| 2015-05-13 | Initiated Coverage | Guggenheim | Buy | $15.00 |
| 2015-04-21 | Boost Price Target | Mizuho | Buy | $13.00 to $16.00 |
| 2015-02-27 | Reiterated Rating | Cantor Fitzgerald | Buy | $16.00 |
| 2015-02-26 | Set Price Target | Cantor Fitzgerald | Buy | $16.00 |
| 2014-12-19 | Set Price Target | Cantor Fitzgerald | Buy | $16.00 |
| 2014-12-19 | Set Price Target | Brean Capital | Buy | $16.00 |
| 2014-10-10 | Initiated Coverage | Oppenheimer | Outperform | $9.00 to $11.00 |
| 2014-09-24 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2014-09-08 | Initiated Coverage | Cantor Fitzgerald | Buy | $16.00 |
| 2014-07-08 | Initiated Coverage | Brean Capital | Buy | $16.00 |
| 2014-06-20 | Lower Price Target | Oppenheimer | Outperform | $10.00 to $8.50 |
| 2014-06-20 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $15.00 to $14.00 |
| 2014-05-02 | Boost Price Target | Mizuho | $12.00 to $13.00 | |
| 2014-05-01 | Upgrade | Cowen and Company | Market Perform to Outperform | |
| 2014-05-01 | Boost Price Target | JPMorgan Chase & Co. | $9.00 to $15.00 | |
| 2013-11-08 | Boost Price Target | Brean Capital | $14.00 to $16.00 | |
| 2012-05-08 | Initiated | Oppenheimer | Outperform | $12 |
| 2016-05-26 | Initiated Coverage | Robert W. Baird | Neutral | $8.00 |
| 2016-05-20 | Reiterated Rating | Brean Capital | Buy | $16.00 |
| 2016-05-20 | Reiterated Rating | Mizuho | Buy | $13.00 |
| 2016-05-03 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-03 | Reiterated Rating | Cowen and Company | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In MACK 46 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 6.84M |
| BlackRock Institutional Trust Company, N.A. | 3.21M |
| Newtyn Management, LLC | 1.77M |
| Point72 Asset Management, L.P. | 1.10M |
| CITY NATIONAL BANK | 0.68M |
| Vanguard Group, Inc | 0.61M |
| DIMENSIONAL FUND ADVISORS LP | 0.47M |
| BlackRock Investment Management, LLC | 0.47M |
| Nantahala Capital Management, LLC | 0.43M |
| TIAA CREF INVESTMENT MANAGEMENT LLC | 0.40M |
| BLACKROCK ADVISORS LLC | 0.28M |
| Airain ltd | 0.24M |
| BlackRock Inc. | 0.21M |
| COLUMBIA CAPITAL LLC | 0.12M |
| Yakira Capital Management, Inc. | 0.12M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| CROCKER GARY L | 2.81% (2943961) | MACK / |
| Mulroy Robert J. President and CEO | 1.61% (1683328) | MACK / |
| Nash Sarah E | 0.91% (955296) | BLKB / KNL / MACK / |
| PORTER MICHAEL E | 0.80% (839448) | MACK / PTC / SMG / |
| Sinskey Anthony J | 0.40% (422543) | MACK / MBLX / |
| Fehr Gordon J. | 0.21% (215143) | MACK / |
| Dresser James van B. | 0.16% (168974) | MACK / |
| Niyikiza Clet M. EVP of Development | 0.14% (141507) | MACK / |
| Dineen John M. | 0.10% (100000) | CTSH / MACK / |
| Schoeberl Birgit M. Head of Discovery | 0.06% (65657) | MACK / |
| Lee Vivian S | 0.06% (65000) | MACK / ZION / |
| Quigley James H. | 0.05% (56500) | HES / MACK / WFC / |
| Stewart Edward J. SVP & Pres, Healthcare Sol | 0.05% (51385) | MACK / |
| Nielsen Ulrik B. SVP and CSO | 0.02% (22681) | MACK / |
| Sullivan William A. CFO and Treasurer | 0.02% (21596) | AGTC / MACK / |
| McClements William M. SVP of Corporate Operations | 0.01% (14072) | MACK / |
UM